

PJ34

Catalog No: tcsc1463



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

344458-19-1

Formula:

$C_{17}H_{17}N_3O_2$

Pathway:

Epigenetics;Cell Cycle/DNA Damage

Target:

PARP;PARP

Purity / Grade:

>98%

Solubility:

DMSO : 30 mg/mL (101.58 mM; Need ultrasonic and warming)

Observed Molecular Weight:

295.34

Product Description


PJ34 is a potent specific inhibitor of **PARP1/2** with **IC₅₀** of 110 nM and 86 nM, respectively.

IC50 & Target: IC50: 110 nM (PARP1), 86 nM (PARP2)^[1]

In Vitro:

PJ34 inhibits the PARP enzyme activity with an IC_{50} of 110 ± 1.9 nM. To compare the neuroprotective properties of other PARP inhibitors in PC12 cells, PJ34 is evaluated using by LDH assay. PJ34 treatment also significantly and concentration dependently attenuates cell death at a concentration ranging from 10^{-7} to 10^{-5} M^[1].

In Vivo: To compare the potency and efficacy with other PARP inhibitors, PJ34 is evaluated at the doses of 3.2 and 10 mg/kg, respectively. PJ34 at the dose of 3.2 mg/kg significantly reduces cortical damage by 33%; however, 10 mg/kg dosing shows reversed effect (17% reduction)^[1]. PJ34 (25 mg/kg) reduces the levels of TNF- α mRNA in ischemic animals by 70% and these values in treated mice do not differ from that of sham or naive animals. Treatment of ischemic mice with PJ34 reduces the level of E-selectin mRNA by 81% and that of ICAM-1 mRNA by 54%, compared to vehicle-treated ischemic mice^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!